IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Merger Arb Mondays (08 Sep) - Kangji, OneConnect, Ashimori, Pacific Ind, RPM, Santos, Zeekr

Mayne Pharma (MYX AU): A Favourable Court Ruling

Weekly Deals Digest (19 Oct) - Mayne, Soft99, Mandom, Kangji, Mandarin Oriental, Genting Malaysia

Mayne Pharma (MYX AU): Twists and Turns as Cosette Chases a Get-Out-Of-Jail-Free Card

Mayne Pharma (MYX AU): Got to Know when to Hold ‘em, when to Fold ’em

Mayne Pharma (MYX AU): Entering Uncharted Territory as the Scheme Vote Passes

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>On 29 August, <a href="https://www.smartkarma.com/entities/mayne-pharma-group-ltd" target="_blank" data-smartkarma-citation="entities:757:1" rel="noopener">Mayne Pharma (MYX AU)</a> reported its FY25 results with underlying EBITDA of A$47 million, which is at the lower end of its guidance range. </li>
<li>At first glance, FY25 results are positive for Mayne as they suggest that the weak 3Q was an aberration and its performance is on an upward trajectory. </li>
<li>However, my analysis suggests that the results provide Cosette with several angles to pursue to bolster its case of a MAC breach. This remains a high-risk/high-reward set-up. </li>
</ul>


On 29 August, Mayne Pharma (MYX AU) reported its FY25 results with underlying EBITDA of A$47 million, which is at the lower end of its guidance range. 
At first glance, FY25 results are positive for Mayne as they suggest that the weak 3Q was an aberration and its performance is on an upward trajectory. 
However, my analysis suggests that the results provide Cosette with several angles to pursue to bolster its case of a MAC breach. This remains a high-risk/high-reward set-up. 


Mayne Pharma (MYX AU): FY25 Results Aid Both Sides